Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.
